Gerald A Evans

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8405404/publications.pdf

Version: 2024-02-01

72 1,999 20 43
papers citations h-index g-index

73 73 73 3962
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nature Reviews Clinical Oncology, 2020, 17 , 268-270.	27.6	333
2	Clinical Practice Guidelines for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2008, 19, 19-53.	1.9	203
3	Complicated Urinary Tract Infection in Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2005, 16, 349-360.	1.9	186
4	Canadian clinical practice guidelines for acute and chronic rhinosinusitis. Allergy, Asthma and Clinical Immunology, $2011, 7, 2$.	2.0	153
5	Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole. PLoS ONE, 2014, 9, e82622.	2.5	72
6	Health technology assessment: A comprehensive framework for evidence-based recommendations in Ontario. International Journal of Technology Assessment in Health Care, 2009, 25, 141-150.	0.5	60
7	Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2010, 21, e122-e150.	1.9	56
8	High incidence of diagnosis with syphilis co-infection among men who have sex with men in an HIV cohort in Ontario, Canada. BMC Infectious Diseases, 2015, 15, 356.	2.9	56
9	The case for relaxing no-visitor policies in hospitals during the ongoing COVID-19 pandemic. Cmaj, 2021, 193, E135-E137.	2.0	54
10	Opportunity Cost of Funding Drugs for Rare Diseases. Medical Decision Making, 2014, 34, 1016-1029.	2.4	53
11	Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009. Journal of Antimicrobial Chemotherapy, 2013, 68, 1505-1509.	3.0	51
12	The evolving epidemiology of <i>Clostridium difficile</i> infection in Canadian hospitals during a postepidemic period (2009–2015). Cmaj, 2018, 190, E758-E765.	2.0	47
13	Canadian Practice Guidelines for Surgical Intra-Abdominal Infections. Canadian Journal of Infectious Diseases and Medical Microbiology, 2010, 21, 11-37.	1.9	40
14	An Evaluation Framework for Funding Drugs for Rare Diseases. Value in Health, 2012, 15, 982-986.	0.3	40
15	Impact of a Fluoroquinolone Restriction Policy in an Elderly Population. American Journal of Medicine, 2007, 120, 893-900.	1.5	39
16	COVID-19 and cancer: do we really know what we think we know?. Nature Reviews Clinical Oncology, 2020, 17, 386-388.	27.6	35
17	The Use of Antiviral Drugs for Influenza: Guidance for Practitioners 2012/2013. Canadian Journal of Infectious Diseases and Medical Microbiology, 2012, 23, e79-e92.	1.9	27
18	The Management of Infection and Colonization due to Methicillin-ResistantStaphylococcus aureus: A CIDS/CAMM Position Paper. Canadian Journal of Infectious Diseases & Medical Microbiology, 2004, 15, 39-48.	0.3	26

#	Article	IF	CITATIONS
19	Long-Term Sequelae and Health-Related Quality of Life Associated With Lyme Disease: A Systematic Review. Clinical Infectious Diseases, 2020, 71, 440-452.	5.8	26
20	A confusing Case –Weissella confusaProsthetic Joint Infection: A Case Report and Review of the Literature. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, 173-175.	1.9	21
21	Toward a Functional Definition of a "Rare Disease―for Regulatory Authorities and Funding Agencies. Value in Health, 2014, 17, 757-761.	0.3	21
22	A recipe for antimicrobial stewardship success: Using intervention mapping to develop a program to reduce antibiotic overuse in long-term care. Infection Control and Hospital Epidemiology, 2019, 40, 24-31.	1.8	21
23	RETIRED: Canadian Consensus Guidelines on Human Papillomavirus. Journal of Obstetrics and Gynaecology Canada, 2007, 29, S1.	0.7	18
24	Application of a Policy Framework for the Public Funding of Drugs for Rare Diseases. Journal of General Internal Medicine, 2014, 29, 774-779.	2.6	18
25	Microbial source tracking and spatial analysis of E. coli contaminated private well waters in southeastern Ontario. Journal of Water and Health, 2014, 12, 348-357.	2.6	17
26	Assessing the magnitude and trends in hospital acquired infections in Canadian hospitals through sequential point prevalence surveys. Antimicrobial Resistance and Infection Control, 2016, 5, 19.	4.1	17
27	A spatial analysis of private well water Escherichia coli contamination in southern Ontario. Geospatial Health, 2013, 8, 65.	0.8	16
28	Emergency Department Surveillance as a Proxy For The Prediction of Circulating Respiratory Viral Disease in Eastern Ontario. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, 150-154.	1.9	16
29	Adequacy of Mental Health Services for HIV-Positive Patients with Depression: Ontario HIV Treatment Network Cohort Study. PLoS ONE, 2016, 11, e0156652.	2.5	16
30	Oral histoplasmosis masquerading as an invasive carcinoma. Journal of Oral and Maxillofacial Surgery, 1995, 53, 1110-1114.	1.2	15
31	Recurrent Chronic Ambulatory Peritoneal Dialysis-Associated Infection due to <i>Rothia dentocariosa</i> . Canadian Journal of Infectious Diseases and Medical Microbiology, 2004, 15, 171-173.	1.9	15
32	Factitious AIDS. New England Journal of Medicine, 1988, 319, 1605-1606.	27.0	13
33	Macrolides: A Canadian Infectious Disease Society Position Paper. Canadian Journal of Infectious Diseases & Medical Microbiology, 2001, 12, 218-231.	0.3	13
34	Acute orbital inflammatory syndrome following H1N1 immunization. Canadian Journal of Ophthalmology, 2011, 46, 552-553.	0.7	13
35	Longitudinal Multicenter Analysis of Outcomes After Cessation of Control Measures for Vancomycin-Resistant Enterococci. Infection Control and Hospital Epidemiology, 2017, 38, 24-30.	1.8	13
36	Mutation of Host Cell Determinants which Discriminate between Lytic and Persistent Mouse Hepatitis Virus Infection Results in a Fusion-resistant Phenotype. Journal of General Virology, 1989, 70, 3335-3346.	2.9	12

#	Article	IF	Citations
37	Antimicrobial use among adult inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program: 2009 to 2016. Antimicrobial Resistance and Infection Control, 2020, 9, 32.	4.1	12
38	Phylogenomics reveals viral sources, transmission, and potential superinfection in early-stage COVID-19 patients in Ontario, Canada. Scientific Reports, 2021, 11, 3697.	3.3	12
39	The oxazolidinones. Current Infectious Disease Reports, 2002, 4, 17-27.	3.0	11
40	AMMI Canada Position Paper: 2012 Mandatory Influenza Immunization of Health Care Workers. Canadian Journal of Infectious Diseases and Medical Microbiology, 2012, 23, e93-e95.	1.9	10
41	Characterization of Healthcare-Associated and Community-Associated <i>Clostridioides difficile</i> Infections among Adults, Canada, 2015–2019. Emerging Infectious Diseases, 2022, 28, .	4.3	10
42	Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for <i>Clostridium difficile</i> infection. Jammi, 2018, 3, 71-92.	0.5	9
43	The Vioxx® legacy: Enduring lessons from the not so distant past. Cardiology Journal, 2014, 21, 203-205.	1.2	9
44	The Use of Antiviral Drugs for Influenza: A Foundation Document for Practitioners. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, 1C-15C.	1.9	8
45	Clostridium sordellii infection and toxin neutralization. Pediatric Infectious Disease Journal, 1990, 9, 582-585.	2.0	7
46	Growth of Coagulase Negative Staphylococci in Peritoneal Dialysate Fluid. ASAIO Journal, 1994, 40, M431-M434.	1.6	7
47	Guidance for Practitioners on the Use of Antiviral Drugs to Control Influenza Outbreaks in Long-Term Care Facilities in Canada, 2014-2015 Season. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, e1-e4.	1.9	7
48	Human granulocytic anaplasmosis acquired from a blacklegged tick in Ontario. Cmaj, 2018, 190, E363-E366.	2.0	7
49	HYPERSENSITIVITY REACTION ASSOCIATED WITH INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR INTERSTITIAL CYSTITIS. Journal of Urology, 2004, 172, 537-537.	0.4	6
50	Burden and risk factors for gastrointestinal symptom distress in HIV patients in the modern antiretroviral era. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 156-167.	1.2	6
51	Sexual behaviors among women living with HIV in Ontario, Canada. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 587-592.	1.2	6
52	Lyme disease: How reliable are serologic results?. Cmaj, 2015, 187, 1193-1194.	2.0	5
53	Estimating direct healthcare costs attributable to laboratoryâ€confirmed Lyme disease in Ontario, Canada: A populationâ€based matched cohort study using health administrative data. Zoonoses and Public Health, 2019, 66, 428-435.	2.2	5
54	Guidance on The Use of Antiviral Drugs for Influenza in Acute Care Facilities in Canada, 2014-2015. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, e5-e8.	1.9	4

#	Article	IF	CITATIONS
55	Use of antiviral drugs for seasonal influenza: Foundation document for practitioners—Update 2019. Jammi, 2019, 4, 60-82.	0.5	4
56	Infection Control for the Otolaryngologist in the Era of Severe Acute Respiratory Syndrome. The Journal of Otolaryngology, 2003, 32, 281.	0.6	4
57	Comparison of coping strategies and supports between aboriginal and non-aboriginal people living with HIV in Ontario. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 63-69.	1.2	3
58	Estimating the population health burden of Lyme disease in Ontario, Canada: a microsimulation modelling approach. CMAJ Open, 2021, 9, E1005-E1012.	2.4	3
59	Antimicrobial Regimens Prescribed by Canadian Physicians for Chemotherapy-Induced Febrile Neutropenic Episodes. Canadian Journal of Infectious Diseases & Medical Microbiology, 1999, 10, 353-357.	0.3	2
60	Application of Operations Research to Funding Decisions for Treatments with Rare Disease. Profiles in Operations Research, 2013, , 281-294.	0.4	2
61	Guidance on the use of antiviral agents for the 2019–2020 influenza season. Jammi, 2020, 5, 57-60.	0.5	2
62	Laboratory diagnosis of human infection with avian influenza. Cmaj, 2006, 175, 1371-1371.	2.0	1
63	The Velvet Myocardium: Potential Harbinger of Death in Acute Myocarditis?. Canadian Journal of Cardiology, 2013, 29, 1742.e25-1742.e27.	1.7	1
64	Renal Failure, Hepatitis and Myocarditis in A Previously Healthy Man. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, 133-134.	1.9	1
65	Guidance on use of antiviral drugs given potential low vaccine effectiveness for the 2017–2018 influenza season. Jammi, 2018, 3, 1-3.	0.5	1
66	Canadian clinical practice guidelines for acute and chronic rhinosinusitis. Executive summary. Journal of Otolaryngology - Head and Neck Surgery, 2011, 40 Suppl 2, S91-8.	1.9	1
67	The Need for Transparency and Efficiency in Reimbursement Decisions Relating to Drugs for Rare Diseases. Medical Decision Making, 2015, 35, 145-147.	2.4	0
68	AÂLongitudinal Four-year Pre-Post Intervention Study Evaluating the Use of an Antimicrobial Stewardship Application. Open Forum Infectious Diseases, 2017, 4, S260-S260.	0.9	0
69	A rare case of pulmonary <i>Mycobacterium szulgai</i> treated with combined drug therapy and bilateral surgical lung resection. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 166-168.	0.5	0
70	Update on influenza antiviral drug treatment and prophylaxis for the 2015–2016 influenza season. Jammi, 2016, 1, 1-4.	0.5	0
71	2020–2021 AMMI Canada guidance on the use of antiviral drugs for influenza in the setting of co-circulation of seasonal influenza and SARS-CoV-2 viruses in Canada. Jammi, 2020, 5, 214-222.	0.5	0
72	The pitfalls of mass hospital health care worker testing forÂCOVID-19. Jammi, 2020, 5, 121-123.	0.5	0